BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22899293)

  • 1. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
    Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
    Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
    Marx AH; Burandt EC; Choschzick M; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Bokemeyer C; Fiedler W; Terracciano L; Sauter G; Izbicki JR
    Hum Pathol; 2010 Nov; 41(11):1577-85. PubMed ID: 20656317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas.
    Hanken H; Gaudin R; Gröbe A; Fraederich M; Eichhorn W; Smeets R; Simon R; Sauter G; Grupp K; Izbicki JR; Sehner S; Heiland M; Blessmann M
    J Oral Pathol Med; 2014 Apr; 43(4):304-8. PubMed ID: 24645976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    Kim EK; Kim KA; Lee CY; Shim HS
    PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
    Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p95HER2 truncated form in resected non-small cell lung cancer.
    Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
    J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH.
    Russell PA; Yu Y; Young RJ; Conron M; Wainer Z; Alam N; Solomon B; Wright GM
    Mod Pathol; 2014 Dec; 27(12):1621-31. PubMed ID: 24762544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
    Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
    Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
    Cho EY; Park K; Do I; Cho J; Kim J; Lee J; Kim S; Kim KM; Sohn TS; Kang WK; Kim S
    Mod Pathol; 2013 May; 26(5):677-84. PubMed ID: 23238628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
    Wilbertz T; Wagner P; Petersen K; Stiedl AC; Scheble VJ; Maier S; Reischl M; Mikut R; Altorki NK; Moch H; Fend F; Staebler A; Bass AJ; Meyerson M; Rubin MA; Soltermann A; Lengerke C; Perner S
    Mod Pathol; 2011 Jul; 24(7):944-53. PubMed ID: 21460799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
    Reichelt U; Duesedau P; Tsourlakis MCh; Quaas A; Link BC; Schurr PG; Kaifi JT; Gros SJ; Yekebas EF; Marx A; Simon R; Izbicki JR; Sauter G
    Mod Pathol; 2007 Jan; 20(1):120-9. PubMed ID: 17143264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 Overexpression and Amplification in Feline Pulmonary Carcinoma.
    Muscatello LV; Oto ED; Dignazzi M; Murphy WJ; Porcellato I; De Maria R; Raudsepp T; Foschini MP; Sforna M; Benazzi C; Brunetti B
    Vet Pathol; 2021 May; 58(3):527-530. PubMed ID: 33461438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study.
    Hirashima N; Takahashi W; Yoshii S; Yamane T; Ooi A
    Mod Pathol; 2001 Jun; 14(6):556-62. PubMed ID: 11406656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
    Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.